• The rates of major complications in RF ablation are listed below.
  • In AF ablation it has decreased from 6% to less than 4%.
  • Less than 1% incidence of AV node injury in AVNRT ablation.
  • 5–11% in VT ablations of structural heart disease.
  • 4.1–8.8% in epicardial VT ablations.


In light of recent reports showing high incidence of silent cerebral infarcts and organized atrial arrhythmias following radiofrequency (RF) atrial fibrillation (AF) ablation, a review of its safety aspects is timely. Serious complications do occur during supraventricular tachycardia (SVT) ablations and knowledge of their incidence is important when deciding whether to proceed with ablation. Evidence is emerging for the probable role of prophylactic ischemic scar ablation to prevent VT. This might increase the number of procedures performed. Here we look at the various complications of RF ablation and also the methods to minimize them. Electronic database was searched for relevant articles from 1990 to 2015. With better awareness and technological advancements in RF ablation the incidence of complications has improved considerably. In AF ablation it has decreased from 6% to less than 4% comprising of vascular complications, cardiac tamponade, stroke, phrenic nerve injury, pulmonary vein stenosis, atrio-esophageal fistula (AEF) and death. Safety of SVT ablation has also improved with less than 1% incidence of AV node injury in AVNRT ablation. In VT ablation the incidence of major complications was 5–11%, up to 3.4%, up to 1.8% and 4.1–8.8% in patients with structural heart disease, without structural heart disease, prophylactic ablations and epicardial ablations respectively. Vascular and pericardial complications dominated endocardial and epicardial VT ablations respectively. Up to 3% mortality and similar rates of tamponade were reported in endocardial VT ablation. Recent reports about the high incidence of asymptomatic cerebral embolism during AF ablation are concerning, warranting more research into its etiology and prevention.


Radiofrequency ablation;Safety;Popping;Stroke;Esophageal tissue injury;Pulmonary vein stenosis;Coronary artery injury;Ventricular tachycardia ablation;PVI;AF ablation;VT ablation;AVNRT ablation;AVRT ablation

1. Introduction

RF ablation has been part of clinical practice for more than two decades and has become an important treatment option for most clinically relevant cardiac arrhythmias. Achieving the optimal balance between efficacy and safety has proven to be challenging. Even though procedure-related acute complications are on the decline by virtue of better knowledge of arrhythmia physiology, experience of particular group with RF ablation and advancements in technology like mapping, cryoablation and newer ablation techniques such as magnetic navigation [1]; [2] ;  [3]. However the incidence of some chronic complications has risen, as procedures became more complex and time consuming.

Catheter ablation procedures are used to treat a diverse range of arrhythmias with vastly different natural histories and alternative treatment options. For the purposes of this review we will consider three broad types of procedures. Pulmonary vein isolation (PVI) for AF ablation for SVT and VT ablation.

Electronic database was searched for relevant articles from 1990 to 2015. Search terms namely radiofrequency ablation, safety, complications, AF, atrio ventricular reentry tachycardia (AVRT), atrio ventricular nodal reentry tachycardia (AVNRT), VT and atrial flutter (A Fl) were used separately and in combination. Out of 5390 articles obtained through this search, 315 journal articles pertaining to safety issues of RF ablation were carefully studied for the review. Prospective and retrospective designs, and review articles were included. Animal studies, in vitro studies, conference proceedings, case reports, comments, and surgical ablation articles were excluded.

2. Atrial fibrillation ablation

The technique of catheter ablation for atrial fibrillation has developed over a relatively short period of time. The incidence of major complications of AF ablation has decreased overtime. Studies from 1995 to 2010 show a reduction in serious complications from 6% to 3.7% of which vascular complications were the commonest [4] ;  [35].

2.1. Cerebrovascular accident

The reported incidence of clinical stroke in AF ablation is much less than 1% [5] ;  [6]. However, there is ample evidence to suggest that the subclinical cerebral embolism during left sided ablations especially pulmonary venous isolation (PVI) for AF is far more common. Asymptomatic cerebral lesion (ACL) was common ranging from 10 to 14% [5] ;  [7]. An even higher incidence of 41% was reported by the MACAP study when more sensitive 3 Tesla MRI imaging was performed [8].

Medi et al. found 13–20% prevalence of cognitive dysfunction at three months in AF patients treated with ablation compared to none in those managed medically [9]. The presence of spontaneous echo contrast and procedural duration before heparin administration were determinants of ACL [10]. Therapeutic periprocedural anticoagulation significantly reduced ACL [11].

The possible embolic sources are thrombus formation on the ablation electrode and sheath, debris from steam popping and charring, preexisting thrombus in the cardiac chamber, air embolus from within the sheath and fresh thrombus formed on damaged endothelial surface of endocardial lesions [5]; [12] ;  [13].

Factors which have been proven to increase embolic risk are increased catheter time in the left atrium (LA), chronicity of AF, activated clotting time (ACT) below 250 seconds, duration of individual ablations, larger LA size, non-irrigated ablation and the presence of spontaneous echo contrast [5] ;  [14]. Periprocedural cardioversion was associated with an increased incidence of embolic stroke in some studies, however this association was not consistent [15]; [5] ;  [7].

Various methods have been used to minimize this embolic complication, however none in isolation or in combination could completely eliminate the risk of cerebral embolization. Intracardiac thrombus causing embolism could be minimized by adequate periprocedural anticoagulation. Several studies have shown the ideal anticoagulation level to be 300–400 s of ACT [5] ;  [13]. Verma et al. successfully reduced silent embolism by submerged introduction of the catheter into its sheath to prevent air entry [13]. Using intracardiac echocardiography (ICE) Ren et al. demonstrated that thrombi mostly formed in the sheath or mapping catheter and could be managed by withdrawing the sheath and catheter from the LA [14]. Periprocedural continuation of Warfarin reduced the incidence of stroke significantly, without increasing major bleeding or tamponade in Kuwahara et al.s study of 3280 AF ablation cases [16].

2.2. Esophageal tissue injury (ETI)

While esophageal injury appears to be common after AF ablation, the incidence of atrio-esophageal fistula (AEF), which is often fatal was rare at 0.05% [17]. The incidence of esophageal injury defined as erythema, hematoma or ulcer was 2.9%–47% [18]; [19]; [20] ;  [21]. Schmidt et al. reported the highest incidence of injury without fistula formation in 47% using the higher temperature, power and time limits of 50 °C, 50 W and 15 seconds of irrigated ablation [21]. The esophagus is often located less than 5 mm from the LA posterior wall and thermally mediated injury occurs due to direct heat transfer [97].

AEF typically occurs subacutely and up to 23 rd day post ablation has been reported [22]. Clinical features are caused by air embolism (stroke) and sepsis, which is associated with high mortality, greater than 80% [23]. The initial symptoms may be subtle and a high index of suspicion is required.

In one study, ETI was successfully averted by limiting esophageal endoluminal temperature rise to 41 °C [19], however this was not a consistent finding. Di Base et al. encountered 17% ETI even when ablation was discontinued at 39 °C of endoluminal temperature [24]. Endoluminal temperature underestimated esophageal tissue temperature by up to 20 °C and it peaked only 25 seconds after esophageal tissue temperature peak in a canine study [25]. Good et al. explained the discrepancy observed in endoluminal temperature by demonstrating more than 2 cm sideways movement of esophagus during conscious sedation, which could move the probe away from the ablation catheter [98].

Various factors such as the energy delivered to the LA posterior wall, LA dilatation, additional ablation lines, LA size, LA-esophageal distance, use of nasogastric tube in general anesthesia, low BMI and chronicity of AF had been identified as predictors of ETI complications [18]; [20] ;  [26]. Strategies used to prevent esophageal injury were reducing power to 25 W, reducing ablation duration to 30 seconds in the posterior wall and ICE guidance to restrict microbubble formation. Martinek et al. showed that esophageal visualization with barium contrast and limiting energy delivery to 15 W was effective in reducing ETI compared to limiting duration of ablation to 5 seconds without reducing power and without esophageal temperature monitoring [18]. None of these methods were successful in completely eliminating ETI [18] ;  [21].

2.3. Left atrial tachycardia

LA tachycardia especially atrial flutter which is usually incessant and poorly tolerated is a common complication of AF ablation [34]. The incidence could be as high as 29% [27] ;  [28]. It was more common in circumferential ablation compared to segmental isolation and also with additional ablation lines [29] ;  [30]. The common mechanism was macroreentry, which was attributed to non-transmural or non-durable lesions and non-contiguous ablation lines leading to reconnections across gaps [31]. The risk was lessened if bidirectional block was demonstrated after ablation. Half of atrial tachycardia cases persisted three months post-ablation warranting repeat ablation [32]. Cummings et al. demonstrated that the treatment need not be linear ablation and often disconnection of the electrically reconnected pulmonary vein was effective [33]. Mitral annular reentry was a common cause of atrial flutter after single ring or box isolation ablation for AF [34].

2.4. Pulmonary vein stenosis

Pulmonary vein stenosis (PVS) is defined as 50% or more narrowing of the venous lumen, and more than 70% stenosis is termed severe [23]. In 2002, Arentz et al. showed 28% incidence of PVS, which in later studies declined to 0.1–1.3% [22]; [35] ;  [36] and only 0.29% needed intervention [37]. This decreasing incidence was due to changing ablation site from pulmonary vein lumen to antrum, reducing power of ablation and adopting additional imaging modalities to better delineate the ostial anatomy [38] ;  [39]. Dong et al. showed that encircling individual veins carried more risk compared to encircling ipsilateral pairs [40].

Patients with exertional dyspnea, which is the commonest symptom usually have stenosis exceeding 70% in multiple veins [39]. CT scan is widely used to diagnose PVS. Holmes et al. identified a small lumen by pulmonary angiography in 50% of patients whom CT scan showed complete occlusion. This finding has treatment implications as total occlusion is not amenable to stenting [39]. MR imaging was also equally useful as CT scanning [23]. Functional assessment with V/Q scan helped in identifying asymptomatic patients with severe stenosis [38] ;  [39]. Progression of stenosis was variable. Saad et al. reported 8.8% progression mainly in first 3 months and regression in 10.4% [38].

Most clinicians perform stenting for residual stenosis after balloon angioplasty, whereas some prefer primary stenting [36] ;  [39]. Even though angioplasty and stenting reduced the incidence of restenosis in patients with symptomatic severe stenosis compared to balloon dilatation alone, the restenosis rates remained high at 30–50% [36]; [38] ;  [39]. Some clinicians prefer to intervene in severe stenosis irrespective of symptoms because progression to complete occlusion could be rapid which might preclude intervention [38] ;  [39].

2.5. Phrenic nerve injury

Phrenic nerve injury (PNI) has a prevalence of 0.1–0.5% after AF ablation [41]. Right PNI is often associated with ablation of the anteroinferior aspect of the right superior pulmonary vein (RSPV) or posteroseptal portion of superior venacava, owing to their close proximity to the nerve [42] ;  [48]. Although less common, left PNI was reported in AF ablation resulting from application of RF energy close to the proximal LA appendage roof [43].

Although up to 31% of patients with PNI can be asymptomatic after AF ablation, dyspnea is a cardinal symptom and is present in all symptomatic patients [43]. Other symptoms include cough and hiccough and the diagnosis is made by the demonstration of diaphragmatic elevation on chest radiograph [43]. In a study by Sacher et al., 66% of patients recovered completely at 36 ± 33 months after ablation, 17% partially recovered and 17% failed to recover [43]. Avoiding PNI may be possible by using high output “pace mapping” in high risk areas before ablation [43].

2.6. Perforation and tamponade

AF ablation carries more risk of perforation up to 2.4% compared to VT and SVT ablations [35]; [44] ;  [45], probably due to the longer catheter manipulation time, higher number of ablations and higher anticoagulation [46]. Using ICE for transeptal puncture and reducing the temperature limit of irrigated ablations to 42 °C had been recommended [6]. A 1.2% incidence of delayed tamponade was reported by Cappato et al. with an average presentation of 12 days post-ablation [47].

Majority of patients responded with pericardiocentesis and very few required surgical closures. Maximal power delivery in excess of 48 W was a significant risk factor for developing cardiac tamponade during atrial ablations and limiting power delivery to less than 42 W reduced the incidence of perforations [45]. The use of ICE in some studies facilitated early detection of effusion before overt hemodynamic instability [6] ;  [44].

2.7. Death

The leading causes of death of 0.15% in the world-wide survey were cardiac tamponade, stroke and atrio esophageal fistula. 22% of deaths occurred after a month, attributed to various causes namely, hematoma causing tracheal compression, intracranial bleeding and esophageal perforation from pre-procedural trans-esophageal echocardiogram use [23].

2.8. Radiation exposure

Catheter ablations for AF may require prolonged fluoroscopy times. Pre-procedural CT scanning for anatomical mapping may further increase the radiation burden. Prolonged radiation exposure during the procedure puts the patient and also the operator at risk of malignancy and genetic abnormalities. Fluoroscopy time for ablation of persistent AF was reported to be 80–100 min [49]. Sixty minutes of radiation exposure translates to 0.03% increased life time risk for fatal malignancies which was higher for obese patients [50]. Newer technologies for navigation such as magnetic navigation and 4D non-fluoroscopic ablation were shown to be effective in reducing fluoroscopy time [1] ;  [51].

2.9. Miscellaneous complications

Mitral valve injury during AF ablation by trapped circular catheter is a rare complication. Surgical extraction is often required to prevent injury to valve apparatus if gentle manipulation fails [23].

Perioesophageal vagal nerve injury usually presents with upper gastrointestinal symptoms following AF ablation and the incidence could be as high as 1%. Abnormal gastric motility and pyloric spasm is usually treated symptomatically however, severe cases need botulinum injection, surgery or gastric pacing. Prevention is similar to that for esophageal tissue injury [99].

Atrial size and contractility improved after most AF ablations suggesting a positive remodeling effect of the intervention. Loss of contractility was proportional to the amount of myocardium damaged as circumferential ablations resulted in more loss of atrial function compared to segmental ablation [32].

Vascular access complications have shown a favorable trend after the practice of ablation with uninterrupted warfarin had started, probably due to lesser use of bridging Enoxaparin. However, they are still the commonest [23] (Table 1).

Table 1. Complications of atrial fibrillation ablation.
Study Type Year Procedure (n) Major complications Death CVA Tamponade PVS AEF PNI Vascular
Worldwide survey [35] Multicenter survey 1995–2002 11,672 6 0.05 0.94 1.22 1.31 (chronic) 0.42 0.74 1
Updated world-wide survey [37] Multicenter survey 2003–2006 20,825 4.5 0.15 0.94 1.31 0.29 (intervention) 0.04 0.17 1.5
Baman et al. [96] Prospective 2007–2010 1295 3.5 0 0.5 1.2 0 0 1.9
Bertaglia et al. [95] Retrospective 2011 2323 4 0 0.3 0.5 0.1 2.2
Stabile et al. [4] Prospective 2011 2167 3.7 0 0.3 0.6 0.1 2.1

AEF—atrio-esophageal fistula.

CVA—cerebrovascular accident (including transient ischemic attack).

PNI—phrenic nerve injury (needing intervention).

2.10. Summary

With better awareness and technological advancements in RF ablation, the incidence of complications has improved considerably. In AF ablation it has decreased from 6% to less than 4% comprising of vascular complications, cardiac tamponade, stroke, PNI, PVS, AEF and death. ACL is a potentially significant issue with possible long-term consequences. Continuing warfarin and strict intra-procedural anticoagulation reduced its incidence. AEF is often a fatal complication, which could be prevented to an extent with esophageal temperature monitoring. Atrial tachycardia post-AF ablation, which is often very symptomatic, is a common complication and the incidence was reduced by demonstrating bidirectional block. Pulmonary vein stenosis is on the decline after circumferential PVI was adopted. Presenting symptom could be only dyspnea and high index of suspicion is required to diagnose. PNI could be prevented by high output pacing in high- risk areas before ablation. Reducing target temperature and also the delivered power reduced the incidence of pericardial tamponade. ICE guidance for transeptal puncture and pericardial monitoring also helped to reduce morbidity with this complication. Vascular access site complications were the commonest, which showed a favorable trend after performing procedure on warfarin.

3. Supraventricular tachycardia ablation

3.1. AV node injury

AV nodal (AVN) injury is predominantly a complication of AVNRT ablation. The incidence had been high initially at 5.6% in the MERF study when the fast pathway was targeted by virtue of its close proximity to the compact AV node [52]. With change in the ablation site to the slow pathways posteroinferior location which is further away from the AV node, the incidence decreased to 0.07%–0.7% [53]; [54] ;  [55].

Ablations for aortic cusp SVT, accessory pathways and outflow tract VT were also associated with this complication [56]. In a 14 year study of 5330 consecutive SVT ablation cases of AVNRT, AVRT, A Fl and AT by O'Hara et al., permanent AVB was observed in 0.22% of AVNRT ablations and 0.17% of AVRT ablations [57]. French registry reported 0.1% and 1.5% incidence of AV nodal injury in AVRT and AVNRT ablations respectively [58].

3.2. Mortality

Calkins et al.s prospective study of SVT ablations (1999) reported 0.1% mortality in AVRT ablations and none in AVNRT ablations [59]. Feldman et al. did not report any death in 1448 AVNRT ablations [53]. However, 0.04% mortality was reported in 1996 from the French registry of more than 5000 predominantly SVT cases [58].

3.3. Miscellaneous complications

Perforation occurred in 0.1–1.3% [60] (Table 2). Complications could occur during atrial flutter ablation as well which was shown by Brembilla-Perrot et al. where they have reported up to 1.6% chance of life threatening complications when an 8 mm tip catheter was used with setting of 70 W, 70 °C, for 60 seconds [61].

Table 2. Complications of supra ventricular tachycardia ablation.
Study Type Year Procedure (n) SVT type (%) AV blocka (%) CVAb (%) Tamponade (%) Death (%)
MERFS [52] Prospective 1987–1992 880 AVNRT 5.6
Feldman et al. [53] Retrospective 1999–2009 1419 AVNRT 0.07
O'Hara et al. [57] Prospective 1993–2006 5330 AVNRT 0.22 0 0 0
AVRT 0.17 0 0.09 0
AT 0 0 0 0
A Fl 0 0 0 0

AP—accessory pathway, AVNRT—AV nodal reentrant tachycardia.

A Fl—atrial flutter.

a. High grade requiring pacemaker implantation.

b. Stroke and TIA.

3.4. Summary

AV nodal injury is the most concerning complication of SVT ablation especially AVNRT and septal accessory pathways. Adoption of slow pathway ablation for AVNRT reduced the incidence to well below 1%.

4. Endocardial and epicardial ventricular tachycardia ablation

The incidence of major complications of VT ablation was reported to be 5–11%, up to 3.4% and up to 1.8% in patients with structural heart disease, without structural heart disease and prophylactic ablations respectively [2]; [46]; [62]; [63]; [64] ;  [65]. Prophylactic, scar VT ablations are those undertaken after the first arrhythmia as opposed to ablation after recurrent ventricular arrhythmias [63] ;  [64]. Up to 8.5% major complication rate was reported in epicardial ablations [66] ;  [67].

In Peichl et al.s study of 722 patients, advanced age, LV dysfunction, renal failure and the proceduralist experience were identified as the predictors of complications [62]. Renal function was the only predictor of complications in VT ablation identified in Bohnen et al.s study [46]. Neither advanced age nor LV dysfunction was a predictor of complications. Age more than 75 years was not a predictor in Inada et al.s study either [68].

4.1. Death

The combined mortality in ischemic and non-ischemic VT ablations ranged from 0 to 3% [46]; [68]; [69]; [70]; [71] ;  [72], which was frequently due to fast VT leading to cardiogenic shock [68]; [71] ;  [73]. Incomplete procedural success was a predictor of in-hospital mortality [72].

4.2. Perforation and tamponade

The incidence of cardiac perforation ranged from 1 to 2.7% [74] ;  [75]. Tokuda et al. reported 1% incidence of cardiac perforation during VT ablation in the largest single center study [74]. More than half of these patients with cardiac perforations required surgical repair if preceded by steam pop and most perforations occurred during thin-walled RV ablation, in particular the outflow tract.

During epicardial ablation, tamponade was the commonest major complication [67] ;  [76], constituting 5.1% out of 7% major complications in a study [67]. Inadvertent RV puncture occurred in 20% of cases during epicardial access without any adverse consequence.

4.3. Coronary artery injury

Coronary artery injury is an uncommon complication of RFA with reported incidence of 0.09% of all ablations [77], and 1.5% of epicardial ablations [67]. Safe distance of ablation from a coronary artery had been suggested from 2 mm to 12 mm by different authors [78]; [79] ;  [80]. The manifestations of coronary injury could be acute, delayed or chronic [67]; [77] ;  [81]. Acute effects included vasospasm, intimal damage and thrombus formation [78] ;  [82]. Chronic effects were fibrosis and thickening of all three layers of the artery [81]. The artery damage was inversely proportional to vessel size [83].

This complication could occur during both endocardial and epicardial ablations performed in close proximity to the coronary arteries. High-risk areas are the posteroseptal region, sub-eustachian isthmus and coronary sinus and its branches. Injury had also been reported following ablations for typical atrial flutter, AVNRT, AVRT and coronary sinus ablations [84].

Acute coronary occlusion warrants angioplasty and stenting [77]. Coronary angiography before energy delivery in the epicardium could help in preventing coronary injury [67].

4.4. Miscellaneous complications

Vascular complications were the commonest in VT ablation, which was reported up to 4.7%. The incidence of CVA ranged from 0% to 1.4% [68]; [69]; [70] ;  [71], while high grade AV block occurred in up to 1.8% [72]; [68] ;  [70].

The use of ICE was found to be useful in early detection of complications and visualization of great arteries and coronaries in outflow tract ablations [3] High output pacing before ablation near the lateral wall of LV should be considered to avoid phrenic nerve injury in epicardial ablations [76]. A dedicated VT ablation multidisciplinary intensive care team, complete with support staff as shown by Della Bella et al. has improved safety of VT ablation with approximately 3% non-vascular major complications. (4% vascular complications) [2] (Table 3).

Table 3. Complications of ventricular tachycardia ablation.
Study Type Year Proc (n) VT type Major complications Death CVA Tamponade Other
Structural heart disease
Sauer et al. [69] Prospective 1999–2005 327 ICM, NICM 2.1% Nil 0.9% 1.2
Euro VT [94] Prospective 1999–2003 63 ICM 1.5% 0 0 0
Bohnen et al. [46] Prospective 2009–2011 250 SHD 6% 0.4% 0.8% 1.4%
Mallidi et al. [70] Meta-analysis 1965–2010 457 SHD 6.3% 1% 1% AV blocka 1.6% Perforation 1%
Tokuda et al. [74] Prospective 1999–2010 226 NICM 5% 0 0 0 Perforation 1.8%
Dinov et al. help-VT study [65] Prospective 2008–2011 227 ICM, DCM 11% 0.4% 0.8% AV block 0.8% Shock 2.2%
Peichl et al. [62] Prospective 2006–2012 473 8% 0 0.8% 0.6% AV block 1.3% Vascular 4.7%
Della Bella et al. [2] Prospective 2007–2012 634 SHD 7% 0.1% 0 2% Vascular 4%
Inada et al. [68] Prospective 1999–2008 285 IVT 7% 3.8% 0.7% 0.7% AV block 1%
Bohnen et al. [46] Prospective 2009–2011 119 IVT 3.4% 0 0.8% 0.8%
Peichl et al. [62] Prospective 2006–2012 249 IVT 2.8% 0 0.4% 0 AV block 0.4% Vascular 1.6%
SMASH VT [64] RCT 2004–2006 64 ICM 0 0 0 0 1 DVT, 1 CCF
VTACH [63] RCT 2002–2006 54 ICM 1.8% 0 1.8% 1 ST elevation
Della Bella et al. [76] Multicenter Survey 2001–2009 218 SHD, NSHD 4.1% 0 0 3.7% 1 abdominal hemorrhage
Sacher et al. [67] Multicenter Survey 2001–2007 136 SHD 7% 0 0 5.1% CA stenosis 0.6%
Tung et al. [66] Single center Survey 2004–2011 109 SHD, NSHD 8.8% 0 0 0 6.7% epicardial bleeding

RCT — randomized controlled trial.

CVA—cerebrovascular accident (including transient ischemic attack).

IVT- Idiopathic Ventricular Tachycardia

SHD- Structural Heart Disease

NSHD- No Structural Heart Disease

ICM- Ischemic Cardiomyopathy

NICM- Non Ischemic Cardiomyopathy

a. High grade requiring pacemaker implantation.

4.5. Summary

VT ablation suffered the highest incidence of complication among RF ablations. The incidence of major complications was 5–11%, up to 3.4%, up to 1.8% and 4.1–8.8% in patients with structural heart disease, without structural heart disease, prophylactic ablations and epicardial ablations respectively. Vascular and pericardial complications dominated endocardial and epicardial VT ablations respectively. Coronary artery injury was more common in epicardial ablation. Up to 3% mortality and similar rates of tamponade were reported in endocardial VT ablation. Dedicated VT multidisciplinary team and ICE guidance during procedure helped to reduce morbidity.

The extremes of age need special mention. In pediatric SVT ablations, Lee et al. reported that the incidence of complications was similar to that in adults [85]. The risk of AVN injury was at maximum with anterior and mid-septal pathways [86]. Death occurred in 0.14% ablations as reported by Vitello et al. in their study of 5000 procedures [87]. Schaffer et al. observed that it was related to the lower body weight, presence of structural heart disease and left sided procedures [88]. Special care needs to be taken to reduce radiation in pediatric population for obvious reasons [89]. Tomaske et al. did not report any complications in 97 pediatric SVT ablations [90].

The impact of advanced age on safety of RF ablations is less clear. Earlier report by Chen et al. in 1996 in 3966 RF ablation procedures, showed that elderly patients were at a higher risk for complications [91]. Piechl et al. also recently reported that the complications in VT ablation were associated with advanced age [62]. However, both Santangeli et al. in AF ablation and Inada et al. in VT ablation did not report increased complication in elderly [68] ;  [92].

5. Newer technology

Magnetic Navigation System (MNS) is a new technological advancement in radiofrequency ablation [93], in which two powerful magnets are used to navigate the magnetic irrigated catheter precisely to the destination. In one study MNS ablations suffered only 0.34% major complications when compared to 3.2% with conventional ablation in 610 consecutive patients with various arrhythmias [1].

Non-fluoroscopic 4D ablation technology, popularly known as MediGuide, uses pre acquired X-ray images to superimpose catheter position. This considerably reduces radiation exposure. Real time tracking of catheter accounting for respiratory and cardiac movements is another advantage [51].

Conflict of interest

No conflict of interest.


  1. [1] T. Bauernfeind, F. Akca, B. Schwagten, et al.; The magnetic navigation system allows safety and high efficacy for ablation of arrhythmias; Europace, 13 (2011), pp. 1015–10121
  2. [2] P. Della Bella, F. Baratto, D. Tsiachris, et al.; Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias. Clinical perspective long-term outcome after ablation; Circulation, 127 (2013), pp. 1359–1368
  3. [3] J.E. Banchs, P. Patel, G.V. Naccarelli, M.D. Gonzalez; Intracardiac echocardiography in complex cardiac catheter ablation procedures; J Interv Card Electrophysiol, 28 (2010), pp. 167–184
  4. [4] G. Stabile, E. Bertaglia, A. Pappone, et al.; Low incidence of permanent complications during catheter ablation for atrial fibrillation using open-irrigated catheters: a multicentre registry; Europace, 16 (2014), pp. 1154–11549
  5. [5] F. Gaita, D. Caponi, M. Pianelli, et al.; Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism?: magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation; Circulation, 122 (2010), pp. 1667–1673
  6. [6] B. Aldhoon, D. Wichterle, P. Peichl, R. Čihák, J. Kautzner; Complications of catheter ablation for atrial fibrillation in a high-volume centre with the use of intracardiac echocardiography; Europace, 15 (2013), pp. 24–32
  7. [7] H. Ichiki, N. Oketani, S. Ishida, et al.; The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran; Pacing Clin. Electrophysiol., 36 (2013), pp. 1328–1335
  8. [8] K.G. Haeusler, L. Koch, J. Herm, et al.; 3 Tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study; J. Cardiovasc. Electrophysiol., 24 (2013), pp. 14–21
  9. [9] C. Medi, L. Evered, B. Silbert, et al.; Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation; J Am Coll Cardiol, 62 (2013), pp. 531–5319
  10. [10] T. Sakamoto, K. Kumagai, S. Nishiuchi, et al.; Predictors of asymptomatic cerebral infarction associated with radiofrequency catheter ablation for atrial fibrillation using an irrigated-tip catheter; Europace, 15 (2013), pp. 332–338
  11. [11] L. Di Biase, F. Gaita, E. Toso, et al.; Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study; Heart Rhythm., 11 (2014), pp. 791–798
  12. [12] C. Herrera Siklódy, T. Deneke, M. Hocini, et al.; Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study; J Am Coll Cardiol, 58 (2011), pp. 681–688
  13. [13] A. Verma, P. Debruyne, S. Nardi, et al.; Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial; Circulation, 6 (2013), pp. 835–842
  14. [14] J.-F. Ren, F.E. Marchlinski, D.J. Callans; Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography; J Am Coll Cardiol, 43 (2004), pp. 1861–1867
  15. [15] T. Deneke, D.-I. Shin, O. Balta, et al.; Postablation asymptomatic cerebral lesions: long-term follow-up using magnetic resonance imaging; Heart Rhythm., 8 (2011), pp. 1705–1711
  16. [16] T. Kuwahara, A. Takahashi, Y. Takahashi, et al.; Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration; J. Cardiovasc. Electrophysiol., 24 (2013), pp. 510–515
  17. [17] C. Pappone, H. Oral, V. Santinelli, et al.; Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation; Circulation, 109 (2004), pp. 2724–2726
  18. [18] M. Martinek, G. Bencsik, J. Aichinger, et al.; Esophageal damage during radiofrequency ablation of atrial fibrillation: impact of energy settings, lesion sets, and esophageal visualization; J. Cardiovasc. Electrophysiol., 20 (2009), pp. 726–733
  19. [19] Halm Ulrich GT, Zachaus Markus, Sack Stephan, Arya Arash, Piorkowski Christopher, Knigge Ingrid, Hindricks Gerhard, Husser Daniela. Thermal esophageal lesions after radiofrequency catheter ablation of left atrial arrhythmias. American College of Gastroenterology. 2010/03//print; 105: 6.
  20. [20] M. Martinek, C. Meyer, S. Hassanein, et al.; Identification of a high-risk population for esophageal injury during radiofrequency catheter ablation of atrial fibrillation: procedural and anatomical considerations; Heart Rhythm., 7 (2010), pp. 1224–1230
  21. [21] M. Schmidt, G. Nölker, H. Marschang, et al.; Incidence of oesophageal wall injury post-pulmonary vein antrum isolation for treatment of patients with atrial fibrillation; Europace., 10 (2008), pp. 205–209
  22. [22] N. Dagres, G. Hindricks, H. Kottkamp, et al.; Complications of atrial fibrillation ablation in a high-volume center in 1,000 procedures: still cause for concern?; J. Cardiovasc. Electrophysiol., 20 (2009), pp. 1014–1019
  23. [23] H. Calkins, K.H. Kuck, R. Cappato, et al.; HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for Patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society; Europace, 14 (2012), pp. 528–606
  24. [24] L. Di Biase, M. Dodig, W. Saliba, et al.; Capsule endoscopy in examination of esophagus for lesions after radiofrequency catheter ablation: a potential tool to select patients with increased risk of complications; J. Cardiovasc. Electrophysiol., 21 (2010), pp. 839–844
  25. [25] J.E. Cummings, C.D. Barrett, K.N. Litwak, et al.; Esophageal luminal temperature measurement underestimates esophageal tissue temperature during radiofrequency ablation within the canine left atrium: comparison between 8 mm tip and open irrigation catheters; J. Cardiovasc. Electrophysiol., 19 (2008), pp. 641–644
  26. [26] A. Rillig, U. Meyerfeldt, R. Birkemeyer, et al.; Oesophageal temperature monitoring and incidence of oesophageal lesions after pulmonary vein isolation using a remote robotic navigation system; Europace, 12 (2010), pp. 655–661
  27. [27] F. Ouyang, M. Antz, S. Ernst, et al.; Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins lessons from double lasso technique; Circulation, 111 (2005), pp. 127–135
  28. [28] C. Pappone, F. Manguso, G. Vicedomini, et al.; Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach; Circulation, 110 (2004), pp. 3036–30342
  29. [29] A. Chugh, H. Oral, K. Lemola, et al.; Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation; Heart Rhythm., 2 (2005), pp. 464–4671
  30. [30] A. Raviele, S. Themistoclakis, A. Rossillo, A. Bonso; Iatrogenic postatrial fibrillation ablation left atrial tachycardia/flutter: how to prevent and treat it?; J. Cardiovasc. Electrophysiol., 16 (2005), pp. 298–2301
  31. [31] F. Ouyang, M. Antz, S. Ernst; Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins. Lessons from double lasso technique; ACC Curr. J. Rev., 14 (2005), p. 33
  32. [32] A. Natale, A. Raviele, T. Arentz, et al.; Venice chart international consensus document on atrial fibrillation ablation; J. Cardiovasc. Electrophysiol., 18 (2007), pp. 560–580
  33. [33] J.E. Cummings, R. Schweikert, W. Saliba, et al.; Left atrial flutter following pulmonary vein antrum isolation with radiofrequency energy: linear lesions or repeat isolation; J. Cardiovasc. Electrophysiol., 16 (2005), pp. 293–297
  34. [34] T.W. Lim, C.H. Koay, R. McCall, V.A. See, D.L. Ross, S.P. Thomas; Atrial arrhythmias after single-ring isolation of the posterior left atrium and pulmonary veins for atrial fibrillation mechanisms and management; Circulation, 1 (2008), pp. 120–126
  35. [35] R. Cappato, H. Calkins, S.-A. Chen, et al.; Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation; Circulation, 111 (2005), pp. 1100–1105
  36. [36] A.C. Skanes, L.J. Gula, R. Yee, A.D. Krahn, G.J. Klein; Pulmonary vein stenosis: intervene early and carry a big stent; J. Cardiovasc. Electrophysiol., 19 (2008), pp. 679–680
  37. [37] R. Cappato, H. Calkins, S.-A. Chen, et al.; Updated worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation; Circulation: Arrhythmia and Electrophysiology (2009)
  38. [38] E.B. Saad, A. Rossillo, C.P. Saad, et al.; Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy; Circulation, 108 (2003), pp. 3102–3107
  39. [39] D.R. Holmes Jr., K.H. Monahan, D. Packer; Pulmonary vein stenosis complicating ablation for atrial fibrillation: clinical spectrum and interventional considerations; J. Am. Coll. Cardiol. Intv., 2 (2009), pp. 267–276
  40. [40] J.U.N. Dong, C.R. Vasamreddy, V. Jayam, et al.; Incidence and predictors of pulmonary vein stenosis following catheter ablation of atrial fibrillation using the anatomic pulmonary vein ablation approach: results from paired magnetic resonance imaging; J. Cardiovasc. Electrophysiol., 16 (2005), pp. 845–8452
  41. [41] A. Gupta, T. Perera, A. Ganesan, et al.; Complications of catheter ablation of atrial fibrillation: a systematic review; Circulation, 6 (2013), pp. 1082–10828
  42. [42] D. Sanchez-Quitana, J.A. Cabrera, V. Climent, J. Farre, A. Weiglein, S.Y. Ho; How close are the phrenic nerves to cardiac structures? Implications for cardiac interventionalists; J. Cardiovasc. Electrophysiol., 16 (2005), pp. 309–313
  43. [43] F. Sacher, K.H. Monahan, S.P. Thomas, et al.; Phrenic nerve injury after atrial fibrillation catheter ablation: characterization and outcome in a multicenter study; J Am Coll Cardiol, 47 (2006), pp. 2498–2503
  44. [44] T.J. Bunch, S.J. Asirvatham, P.A. Friedman, et al.; Outcomes after cardiac perforation during radiofrequency ablation of the atrium; J. Cardiovasc. Electrophysiol., 16 (2005), pp. 1172–1179
  45. [45] L.-F. Hsu, P. JaÏS, M. Hocini, et al.; Incidence and prevention of cardiac tamponade complicating ablation for atrial fibrillation; Pacing Clin. Electrophysiol., 28 (2005) S106-S9
  46. [46] M. Bohnen, W.G. Stevenson, U.B. Tedrow, et al.; Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias; Heart Rhythm., 8 (2011), pp. 1661–1666
  47. [47] Cappato R, Calkins H, Chen S-A, et al. Delayed cardiac tamponade after radiofrequency catheter ablation of atrial fibrillation: a worldwide report. J Am Coll Cardiol. 58: 2696–7.
  48. [48] F. Sacher, K.H. Monahan, S.P. Thomas, et al.; Phrenic nerve injury after atrial fibrillation catheter ablation. Characterization and outcome in a multicenter study; J Am Coll Cardiol, 47 (2006), pp. 2498–2503
  49. [49] M.D. O'Neill, M. Wright, S. Knecht, et al.; Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint; Eur. Heart J., 30 (2009), pp. 1105–1112
  50. [50] P. Kovoor, M. Ricciardello, L. Collins, J.B. Uther, D.L. Ross; Risk to patients from radiation associated with radiofrequency ablation for supraventricular tachycardia; Circulation, 98 (1998), pp. 1534–1540
  51. [51] T. Gaspar, S. Kircher, A. Arya, et al.; Enhancement of intracardiac navigation by new GPS-guided location system (MediGuide Technologies); Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology14 (2012) ii24-ii5
  52. [52] Cardiology GHobotMERSIotWGoAotESo; Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients: results of the multicenter european radiofrequency survey (MERFS); Eur. Heart J., 17 (1996), pp. 82–88
  53. [53] A. Feldman, A. Voskoboinik, S. Kumar, et al.; Predictors of acute and long-term success of slow pathway ablation for atrioventricular nodal reentrant tachycardia: a single center series of 1,419 consecutive patients; Pacing Clin. Electrophysiol., 34 (2011), pp. 927–933
  54. [54] A. Opel, S. Murray, N. Kamath, et al.; Cryoablation versus radiofrequency ablation for treatment of atrioventricular nodal reentrant tachycardia: cryoablation with 6-mm-tip catheters is still less effective than radiofrequency ablation; Heart Rhythm., 7 (2010), pp. 340–343
  55. [55] B. Brembilla-Perrot, P. Houriez, D. Beurrier, L. Jacquemin; Incidence et pronostic du bloc auriculoventriculaire induit par l'ablation par radiofréquence des tachycardies par réentrée intranodale étude multicentrique; Arch. Mal. Coeur Vaiss., 93 (2000), pp. 1179–1187
  56. [56] J. Park, J. Wi, B. Joung, et al.; Prevalence, risk, and benefits of radiofrequency catheter ablation at the aortic cusp for the treatment of mid to anteroseptal supra-ventricular tachyarrhythmias; Int. J. Cardiol., 167 (2013), pp. 981–986
  57. [57] G.E. O'Hara, F. Philippon, J. Champagne, et al.; Catheter ablation for cardiac arrhythmias: a 14-year experience with 5330 consecutive patients at the Quebec heart institute Laval Hospital; Can. J. Cardiol., 23 (2007), pp. 67B–70B
  58. [58] B. BrembillaPerrot, D. Beurrier, L. Jacquemin, et al.; Complications of radiofrequency ablation: the french experience; Arch. Mal. Coeur Vaiss., 89 (1996), pp. 1599–1605
  59. [59] H. Calkins, P. Yong, J.M. Miller, et al.; Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial; Circulation, 99 (1999), pp. 262–270
  60. [60] H. Go; The multicentre european radiofrequency survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias; Eur. Heart J., 14 (1993), pp. 1644–1653
  61. [61] B. Brembilla-Perrot, M.L. Filali, P.Y. Zinzius, et al.; Is ablation of atrial flutter always safe?; Pacing Clin. Electrophysiol., 35 (2012), pp. 1061–1066
  62. [62] P. Peichl, D. Wichterle, L. Pavlu, R. Cihak, B. Aldhoon, J. Kautzner; Complications of catheter ablation of ventricular tachycardia: a single center experience; Circulation (2014)
  63. [63] Kuck K-H, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 375: 31-40.
  64. [64] V.Y.M.D. Reddy, M.R.M.D. Reynolds, P.M.D.P. Neuzil, et al.; Prophylactic catheter ablation for the prevention of defibrillator therapy; N. Engl. J. Med., 357 (2007), pp. 2657–2665
  65. [65] B. Dinov, L. Fiedler, R. Schonbauer, et al.; Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy results from the prospective heart centre of leipzig VT (HELP-VT) study; Circulation, 129 (2014), pp. 728–736
  66. [66] R. Tung, Y. Michowitz, R. Yu, et al.; Epicardial ablation of ventricular tachycardia: an institutional experience of safety and efficacy; Heart Rhythm., 10 (2013), pp. 490–498
  67. [67] F. Sacher, K. Roberts-Thomson, P. Maury, et al.; Epicardial ventricular tachycardia ablation: a multicenter safety study; J. Am. Coll. Cardiol., 55 (2010), pp. 2366–2372
  68. [68] K. Inada, K.C. Roberts-Thomson, J. Seiler, et al.; Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease; Heart Rhythm., 7 (2010), pp. 740–744
  69. [69] W.H. Sauer, E. Zado, E.P. Gerstenfeld, F.E. Marchlinski, D.J. Callans; Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator; Heart Rhythm., 7 (2010), pp. 9–14
  70. [70] J. Mallidi, G.N. Nadkarni, R.D. Berger, H. Calkins, S. Nazarian; Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease; Heart Rhythm., 8 (2011), pp. 503–510
  71. [71] W.G. Stevenson, D.J. Wilber, A. Natale, et al.; Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial; Circulation, 118 (2008), pp. 2773–2782
  72. [72] B. Dinov, L. Bertagnolli, L. Fiedler, et al.; Complications, procedure-related and in-hospital mortality after catheter ablation for ventricular tachycardia in ischemic and non-ischemic dilated cardiomyopathy; Eur. Heart J., 34 (2013)
  73. [73] R. De Ponti; Role of catheter ablation of ventricular tachycardia associated with structural heart disease; World J. Cardiol., 3 (2011), p. 339
  74. [74] M. Tokuda, P. Kojodjojo, L.M. Epstein, et al.; Outcomes of cardiac perforation complicating catheter ablation of ventricular arrhythmias; Circulation, 4 (2011), pp. 660–666
  75. [75] H. Calkins, A. Epstein, D. Packer, et al.; Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study; J. Am. Coll. Cardiol., 35 (2000), pp. 1905–1914
  76. [76] P. Della Bella, J. Brugada, K. Zeppenfeld, et al.; Epicardial ablation for ventricular tachycardia a european multicenter study; Circulation., 4 (2011), pp. 653–659
  77. [77] K.C. Roberts-Thomson, D. Steven, J. Seiler, et al.; Coronary artery injury due to catheter ablation in adults: presentations and outcomes; Circulation, 120 (2009), pp. 1465–1473
  78. [78] H. Aoyama, H. Nakagawa, J.V. Pitha, et al.; Comparison of cryothermia and radiofrequency current in safety and efficacy of catheter ablation within the canine coronary sinus close to the left circumflex coronary artery; J. Cardiovasc. Electrophysiol., 16 (2005), pp. 1218–1226
  79. [79] R.G. Demaria, P. Pagé, T.K. Leung, et al.; Surgical radiofrequency ablation induces coronary endothelial dysfunction in porcine coronary arteries; Eur. J. Cardiothorac. Surg., 23 (2003), pp. 277–282
  80. [80] E. Sosa, M. Scanavacca, A. d'Avila; Transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia; Curr Cardiol Rep, 3 (2001), pp. 451–458
  81. [81] M. Pons, L. Beck, F. Leclercq, M. Ferriere, B. Albat, J.-M. Davy; Chronic left main coronary artery occlusion: a complication of radiofrequency ablation of idiopathic left ventricular tachycardia; Pacing Clin. Electrophysiol., 20 (1997), pp. 1874–1876
  82. [82] A. Castaño, T. Crawford, M. Yamazaki, U.M.R. Avula, J. Kalifa; Coronary artery pathophysiology after radiofrequency catheter ablation: review and perspectives; Heart Rhythm, 8 (2011), pp. 1975–1980
  83. [83] A. D'Avila, P. Gutierrez, M. Scanavacca, et al.; Effects of radiofrequency pulses delivered in the vicinity of the coronary arteries: implications for nonsurgical transthoracic epicardial catheter ablation to treat ventricular tachycardia; Pacing Clin. Electrophysiol., 25 (2002), pp. 1488–1495
  84. [84] S. Ouali, F. Anselme, A. SavourÉ, A. Cribier; Acute coronary occlusion during radiofrequency catheter ablation of typical atrial flutter; J. Cardiovasc. Electrophysiol., 13 (2002), pp. 1047–1049
  85. [85] P.C. LEE, B. Hwang, S.A. CHEN, et al.; The results of radiofrequency catheter ablation of supraventricular tachycardia in children; Pacing Clin. Electrophysiol., 30 (2007), pp. 655–661
  86. [86] M.S. Schaffer, M.J. Silka, B.A. Ross, J.D. Kugler, society* aPMotPE; Inadvertent atrioventricular block during radiofrequency catheter ablation: results of the pediatric radiofrequency ablation registry; Circulation, 94 (1996), pp. 3214–3220
  87. [87] R. Vitiello, B.W. McCrindle, D. Nykanen, R.M. Freedom, L.N. Benson; Complications associated with pediatric cardiac catheterization; J Am Coll Cardiol, 32 (1998), pp. 1433–1440
  88. [88] M.S. Schaffer, R.M. Gow, J.P. Moak, J.P. Saul; Mortality following radiofrequency catheter ablation (from the pediatric radiofrequency ablation registry); Am. J. Cardiol., 86 (2000), pp. 639–643
  89. [89] K. Bacher, E. Bogaert, R. Lapere, D. De Wolf, H. Thierens; Patient-specific dose and radiation risk estimation in pediatric cardiac catheterization; Circulation, 111 (2005), pp. 83–89
  90. [90] M. Tomaske, R. Candinas, M. Weiss, U. Bauersfeld; Safety and efficacy of paediatric outpatient radiofrequency catheter ablations; Int. J. Cardiol., 148 (2011), pp. 276–279
  91. [91] C. Shih-Ann, C. Chern-En, T. Ching-Tai, et al.; Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: an eight-year survey of 3,966 consecutive procedures in a tertiary referral center; Am. J. Cardiol., 77 (1996), pp. 41–46
  92. [92] P. Santangeli, L.D. BIASE, P. Mohanty, et al.; Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes; J. Cardiovasc. Electrophysiol., 23 (2012), pp. 687–693
  93. [93] J. Bradfield, R. Tung, R. Mandapati, N.G. Boyle, K. Shivkumar; Catheter ablation utilizing remote magnetic navigation: a review of applications and outcomes; Pacing Clin. Electrophysiol., 35 (2012), pp. 1021–1034
  94. [94] H. Tanner, G. Hindricks, M. Volkmer, et al.; Catheter Ablation of Recurrent Scar-Related Ventricular Tachycardia Using Electroanatomical Mapping and Irrigated Ablation Technology: Results of the Prospective Multicenter Euro-VT-Study; J. Cardiovasc. Electrophysiol., 21 (2010), pp. 47–53
  95. [95] E. Bertaglia, G. Stabile, A. Pappone, et al.; Updated National Multicenter Registry on Procedural Safety of Catheter Ablation for Atrial Fibrillation; J. Cardiovasc. Electrophysiol, 24 (2013), pp. 1069–1074
  96. [96] T.S. Baman, K. Jongnarangsin, A. Chugh, et al.; Prevalence and Predictors of Complications of Radiofrequency Catheter Ablation for Atrial Fibrillation; J. Cardiovasc. Electrophysiol, 22 (2011), pp. 626–631
  97. [97] D. Sánchez-Quintana, J.A. Cabrera, V. Climent, J. Farré, M.C. de Mendonça, S.Y. Ho; Anatomic Relations Between the Esophagus and Left Atrium and Relevance for Ablation of Atrial Fibrillation; Circulation, 112 (2005), pp. 1400–1405
  98. [98] E. Good, H. Oral, K. Lemola, et al.; Movement of the Esophagus During Left Atrial Catheter Ablation for Atrial Fibrillation; J. Am. Coll. Cardiol., 46 (2005), pp. 2107–2110
  99. [99] T. Kuwahara, A. Takahashi, Y. Takahashi, et al.; Clinical Characteristics and Management of Periesophageal Vagal Nerve Injury Complicating Left Atrial Ablation of Atrial Fibrillation: Lessons from Eleven Cases; J. Cardiovasc. Electrophysiol, 24 (2013), pp. 847–851
Back to Top

Document information

Published on 19/05/17
Submitted on 19/05/17

Licence: Other

Document Score


Views 34
Recommendations 0

Share this document

claim authorship

Are you one of the authors of this document?